Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.
- Bohlius J 1 University of Bern, Bern, Switzerland.
- Bohlke K 2 American Society of Clinical Oncology, Alexandria, VA.
- Castelli R 3 University of Milan, Milan, Italy.
- Djulbegovic B 4 City of Hope, Duarte, CA.
- Lustberg MB 5 Ohio State University, Columbus, OH.
- Martino M 6 Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy.
- Mountzios G 7 Henry Dunant Hospital Center Athens, Greece.
- Peswani N 8 Advocate Medical Group, Orland Park, IL.
- Porter L 9 Independent Patient Advocate, Washington, DC.
- Tanaka TN 10 UC San Diego Moores Cancer Center, La Jolla, CA.
- Trifirò G 11 University of Messina, Messina, Italy.
- Yang H 12 Thomas Jefferson University, Philadelphia, PA.
- Lazo-Langner A 13 Western University, London, Ontario, Canada.
- 2019-04-11
Published in:
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology. - 2019
Anemia
Biosimilar Pharmaceuticals
Hematinics
Humans
Meta-Analysis as Topic
Neoplasms
Randomized Controlled Trials as Topic
English
PURPOSE
To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.
METHODS
PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs in patients with cancer published from January 31, 2010, through May 14, 2018. For biosimilar ESAs, the literature search was expanded to include meta-analyses and RCTs in patients with cancer or chronic kidney disease and cohort studies in patients with cancer due to limited RCT evidence in the cancer setting. ASCO and ASH convened an Expert Panel to review the evidence and revise previous recommendations as needed.
RESULTS
The primary literature review included 15 meta-analyses of RCTs and two RCTs. A growing body of evidence suggests that adding iron to treatment with an ESA may improve hematopoietic response and reduce the likelihood of RBC transfusion. The biosimilar literature review suggested that biosimilars of epoetin alfa have similar efficacy and safety to reference products, although evidence in cancer remains limited.
RECOMMENDATIONS
ESAs (including biosimilars) may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent and whose hemoglobin has declined to < 10 g/dL. RBC transfusion is also an option. With the exception of selected patients with myelodysplastic syndromes, ESAs should not be offered to most patients with nonchemotherapy-associated anemia. During ESA treatment, hemoglobin may be increased to the lowest concentration needed to avoid transfusions. Iron replacement may be used to improve hemoglobin response and reduce RBC transfusions for patients receiving ESA with or without iron deficiency. Additional information is available at www.asco.org/supportive-care-guidelines and www.hematology.org/guidelines .
To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.
METHODS
PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs in patients with cancer published from January 31, 2010, through May 14, 2018. For biosimilar ESAs, the literature search was expanded to include meta-analyses and RCTs in patients with cancer or chronic kidney disease and cohort studies in patients with cancer due to limited RCT evidence in the cancer setting. ASCO and ASH convened an Expert Panel to review the evidence and revise previous recommendations as needed.
RESULTS
The primary literature review included 15 meta-analyses of RCTs and two RCTs. A growing body of evidence suggests that adding iron to treatment with an ESA may improve hematopoietic response and reduce the likelihood of RBC transfusion. The biosimilar literature review suggested that biosimilars of epoetin alfa have similar efficacy and safety to reference products, although evidence in cancer remains limited.
RECOMMENDATIONS
ESAs (including biosimilars) may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent and whose hemoglobin has declined to < 10 g/dL. RBC transfusion is also an option. With the exception of selected patients with myelodysplastic syndromes, ESAs should not be offered to most patients with nonchemotherapy-associated anemia. During ESA treatment, hemoglobin may be increased to the lowest concentration needed to avoid transfusions. Iron replacement may be used to improve hemoglobin response and reduce RBC transfusions for patients receiving ESA with or without iron deficiency. Additional information is available at www.asco.org/supportive-care-guidelines and www.hematology.org/guidelines .
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1200/JCO.18.02142
- PMID 30969847
- Persistent URL
- https://sonar.ch/global/documents/185177
Statistics
Document views: 26
File downloads:
- Full-text: 0